StockTipsArenaBeta

BUY Alembic Pharmaceuticals Limited — Nagaraj Shetty, HDFC Securities

BUYAlembic Pharmaceuticals Limited
Alembic Pharmaceuticals share price target & all analyst calls

byNagaraj Shetty, HDFC SecuritiesHorizon: NA (inferred Swing (≤2wk))4 Nov 2026via ET Now

Entry₹919.7Inferred
Target₹1,000
Total upside +8.73%
Stop lossNot given
CMP₹965.151d ago
Active+4.94%+3.61%upside left 12d left
Follow Nagaraj Shetty for new calls(37% target hit, 75 closed calls)Get alertsWatch APLLTD for new buy/sell callsGet alertsSee 203 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:21 pm IST
8 supporting1 neutral1 opposing
Supports the BUY call (8)

MACD above its signal line — bullish momentum

Technicals · macd·7 Nov · today

Past week's volume 4.0× the 30-day average

Technicals · volume·6 Nov · yesterday

Alembic Pharmaceuticals received final approval from the USFDA for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC).

BSE · Company Update·4 Nov · 2d ago

(opens in new tab)

Alembic Pharmaceuticals Q2 Results: Shares jump 20% after profit rises 81%; US business grows 77%

NewsCnbc-Tv18·4 Nov · 3d ago

(opens in new tab)

Alembic Pharmaceuticals has expanded its strategic collaboration with DifGen Pharmaceuticals to develop and commercialize a portfolio of over 20 complex generic products in the US market.

BSE · Company Update·4 Nov · 3d ago

(opens in new tab)
Neutral / worth noting (1)

Please find attached Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026.

BSE · Board Meeting·4 Nov · 3d ago

(opens in new tab)
Weighs against the BUY call (1)

RSI at 83 — overbought territory

Technicals · rsi·7 Nov · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Alembic Pharmaceuticals

All analyst calls on Alembic Pharmaceuticals

More from Nagaraj Shetty, HDFC Securities

Every call and its outcome